The international consortium on the Ehlers–Danlos syndromes

on behalf of the Steering Committee of The International Consortium on the Ehlers-Danlos Syndromes

Research output: Contribution to journalEditorial

Abstract

Since 1998, two developments have led to concerns that the EDS nosology needs to be substantially revised. The first development was the clinical and molecular characterization of several new EDS variants, which substantially broadened the molecular basis underlying EDS. The second was the growing concern, in the absence of genetic diagnosis, that the hypermobile type of EDS had an expanded phenotype, may be genetically heterogeneous, and that the diagnostic criteria currently in use were inadequate. Furthermore, there is a dire need for the development of guidelines for management for each type of EDS to allow both the specialist and the generalist to care for affected individuals and their families. We have been meeting together as an international consortium over the past 2 years to establish these new criteria and management and care guidelines

Original languageEnglish (US)
Pages (from-to)5-7
Number of pages3
JournalAmerican Journal of Medical Genetics, Part C: Seminars in Medical Genetics
Volume175
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Guidelines
Phenotype

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

on behalf of the Steering Committee of The International Consortium on the Ehlers-Danlos Syndromes (2017). The international consortium on the Ehlers–Danlos syndromes. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 175(1), 5-7. https://doi.org/10.1002/ajmg.c.31547

The international consortium on the Ehlers–Danlos syndromes. / on behalf of the Steering Committee of The International Consortium on the Ehlers-Danlos Syndromes.

In: American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, Vol. 175, No. 1, 01.03.2017, p. 5-7.

Research output: Contribution to journalEditorial

on behalf of the Steering Committee of The International Consortium on the Ehlers-Danlos Syndromes 2017, 'The international consortium on the Ehlers–Danlos syndromes', American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, vol. 175, no. 1, pp. 5-7. https://doi.org/10.1002/ajmg.c.31547
on behalf of the Steering Committee of The International Consortium on the Ehlers-Danlos Syndromes. The international consortium on the Ehlers–Danlos syndromes. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics. 2017 Mar 1;175(1):5-7. https://doi.org/10.1002/ajmg.c.31547
on behalf of the Steering Committee of The International Consortium on the Ehlers-Danlos Syndromes. / The international consortium on the Ehlers–Danlos syndromes. In: American Journal of Medical Genetics, Part C: Seminars in Medical Genetics. 2017 ; Vol. 175, No. 1. pp. 5-7.
@article{f22c0b65cec24c5cb6b2e29379f28b7e,
title = "The international consortium on the Ehlers–Danlos syndromes",
abstract = "Since 1998, two developments have led to concerns that the EDS nosology needs to be substantially revised. The first development was the clinical and molecular characterization of several new EDS variants, which substantially broadened the molecular basis underlying EDS. The second was the growing concern, in the absence of genetic diagnosis, that the hypermobile type of EDS had an expanded phenotype, may be genetically heterogeneous, and that the diagnostic criteria currently in use were inadequate. Furthermore, there is a dire need for the development of guidelines for management for each type of EDS to allow both the specialist and the generalist to care for affected individuals and their families. We have been meeting together as an international consortium over the past 2 years to establish these new criteria and management and care guidelines",
author = "{on behalf of the Steering Committee of The International Consortium on the Ehlers-Danlos Syndromes} and Lara Bloom and Peter Byers and Francomano, {Clair Ann} and Brad Tinkle and Fransiska Malfait",
year = "2017",
month = "3",
day = "1",
doi = "10.1002/ajmg.c.31547",
language = "English (US)",
volume = "175",
pages = "5--7",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - The international consortium on the Ehlers–Danlos syndromes

AU - on behalf of the Steering Committee of The International Consortium on the Ehlers-Danlos Syndromes

AU - Bloom, Lara

AU - Byers, Peter

AU - Francomano, Clair Ann

AU - Tinkle, Brad

AU - Malfait, Fransiska

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Since 1998, two developments have led to concerns that the EDS nosology needs to be substantially revised. The first development was the clinical and molecular characterization of several new EDS variants, which substantially broadened the molecular basis underlying EDS. The second was the growing concern, in the absence of genetic diagnosis, that the hypermobile type of EDS had an expanded phenotype, may be genetically heterogeneous, and that the diagnostic criteria currently in use were inadequate. Furthermore, there is a dire need for the development of guidelines for management for each type of EDS to allow both the specialist and the generalist to care for affected individuals and their families. We have been meeting together as an international consortium over the past 2 years to establish these new criteria and management and care guidelines

AB - Since 1998, two developments have led to concerns that the EDS nosology needs to be substantially revised. The first development was the clinical and molecular characterization of several new EDS variants, which substantially broadened the molecular basis underlying EDS. The second was the growing concern, in the absence of genetic diagnosis, that the hypermobile type of EDS had an expanded phenotype, may be genetically heterogeneous, and that the diagnostic criteria currently in use were inadequate. Furthermore, there is a dire need for the development of guidelines for management for each type of EDS to allow both the specialist and the generalist to care for affected individuals and their families. We have been meeting together as an international consortium over the past 2 years to establish these new criteria and management and care guidelines

UR - http://www.scopus.com/inward/record.url?scp=85015678195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015678195&partnerID=8YFLogxK

U2 - 10.1002/ajmg.c.31547

DO - 10.1002/ajmg.c.31547

M3 - Editorial

C2 - 28306227

AN - SCOPUS:85015678195

VL - 175

SP - 5

EP - 7

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 1

ER -